Generate Biomedicines, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Generate Biomedicines, Inc. (GENB) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 24.38 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-06
- Generate Biomedicines, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 24.59M shares, a 73.10% decline year-over-year.
- Generate Biomedicines, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 91.40M shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month |
|---|---|---|
| 2026-06-30 | 24.38M shares 10-Q · filed 2026-08-06 | |
| 2026-03-31 | 24.59M shares 10-Q · filed 2026-05-07 | |
| 2025-06-30 | 91.31M shares 10-Q · filed 2026-08-06 | |
| 2025-03-31 | 91.40M shares 10-Q · filed 2026-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |